Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Other Operating Expenses (2016 - 2023)

Celldex Therapeutics (CLDX) has 14 years of Other Operating Expenses data on record, last reported at -$12.5 million in Q4 2023.

  • For Q4 2023, Other Operating Expenses fell 32794.74% year-over-year to -$12.5 million; the TTM value through Sep 2024 reached -$12.5 million, down 32794.74%, while the annual FY2023 figure was -$12.5 million, 282.16% down from the prior year.
  • Other Operating Expenses reached -$12.5 million in Q4 2023 per CLDX's latest filing, down from -$38000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $5.1 million in Q2 2020 and bottomed at -$15.0 million in Q2 2022.
  • Average Other Operating Expenses over 5 years is -$1.3 million, with a median of -$136000.0 recorded in 2020.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 1125.0% in 2021, then crashed 32794.74% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at -$318000.0 in 2019, then skyrocketed by 106.29% to $20000.0 in 2020, then surged by 1125.0% to $245000.0 in 2021, then plummeted by 115.51% to -$38000.0 in 2022, then plummeted by 32794.74% to -$12.5 million in 2023.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were -$12.5 million in Q4 2023, -$38000.0 in Q4 2022, and -$15.0 million in Q2 2022.